Receptor News and Research

RSS

Lung cancer patients with Del19 mutation benefit most from afatinib

Afatinib has been approved in Germany since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI).

20 Feb 2014

Certain fragments of DNA shed by tumors can be used to non-invasively screen for early-stage cancers

Certain fragments of DNA shed by tumors into the bloodstream can potentially be used to non-invasively screen for early-stage cancers, monitor responses to treatment and help explain why some cancers are resistant to therapies, according to results of an international study led by Johns Hopkins Kimmel Cancer Center investigators.

20 Feb 2014

Deficiency in SNX27 explains learning impairment in Down's syndrome

Scientists at A*STAR's Institute of Molecular and Cell Biology (IMCB) have identified the precise role of the protein, SNX27, in the pathway leading to memory and learning impairment.

20 Feb 2014

PBL Assay Science, HumanZyme ink licensing agreement to expand reagent offerings

PBL Assay Science announces a licensing agreement with HumanZyme, Inc. (Chicago, USA) to expand reagent offerings. The agreement allows PBL to provide ~50 authentic human cell-expressed (HCE) cytokines and growth factors directly to scientists worldwide.

From PBL Assay Science 20 Feb 2014

Eleven Biotherapeutics announces first pivotal Phase 3 clinical study of EBI-005 for treatment of DED

Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that patient randomization and dosing are underway in the Company's first pivotal Phase 3 clinical study of EBI-005 for the treatment of moderate to severe dry eye disease (DED), the OASIS study (A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Control In Subjects With Moderate to Severe Dry Eye Disease).

19 Feb 2014

Taste receptors act as first line sentinels against infection in upper airway

The body uses mucus as a protective barrier to defend against pathogens, toxins, and allergens in the upper respiratory tract that can lead to such conditions as chronic sinusitis.

19 Feb 2014

Researchers discover protein for treatment of anaplastic thyroid carcinoma

Anaplastic thyroid carcinoma (ATC) is an aggressive type of cancer with a poor prognosis for which there is currently no effective treatment. Researchers from the National University of Singapore (NUS) have discovered for the first time that an epithelial basement membrane protein, called laminin-5 gamma-2 (LAMC2), has the potential to be an ideal target for the treatment of ATC.

19 Feb 2014

NPS Pharmaceuticals reports net global product sales of $15.3 million for Q4 2013

NPS Pharmaceuticals, Inc., a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today reported financial results for 2013 and its financial outlook for 2014.

18 Feb 2014

IGF1R linked to mutation-negative lung cancer erlotinib resistance

Activation of the insulin-like growth factor 1 receptor plays a key role in acquired resistance to erlotinib in lung cancer with wild-type epidermal growth factor receptor, research suggests.

18 Feb 2014

Study shows how immune system reconstitutes itself following immune-depleting therapy

A new study describes the complexity of the new T cell repertoire following immune-depleting therapy to treat multiple sclerosis, improving our understanding of immune tolerance and clinical outcomes.

18 Feb 2014

NUS researchers discover promising treatment for anaplastic thyroid carcinoma

Anaplastic thyroid carcinoma is an aggressive type of cancer with a poor prognosis for which there is currently no effective treatment. Researchers from the National University of Singapore have discovered for the first time that an epithelial basement membrane protein, called laminin-5 gamma-2 (LAMC2), has the potential to be an ideal target for the treatment of ATC.

18 Feb 2014

Researchers detail how psoralen blocks signaling pathway of HER2-positive cancers

A common compound known to fight lymphoma and skin conditions actually has a second method of action that makes it particularly deadly against certain aggressive breast tumors, researchers at Duke Medicine report.

18 Feb 2014

Afatinib ‘first line’ for advanced mutation-positive lung cancer

Afatinib should be given as a first-line treatment for Asian patients with advanced, epidermal growth factor receptor mutation-positive, non-small-cell lung cancer, researchers recommend.

17 Feb 2014

Study points to unique therapeutic approach for managing muscle-wasting conditions

New findings on why skeletal muscle stem cells stop dividing and renewing muscle mass during aging points up a unique therapeutic opportunity for managing muscle-wasting conditions in humans, says a new University of Colorado Boulder study.

17 Feb 2014

New research points to potential target for treating triple negative breast cancer

New research from the University of Michigan Comprehensive Cancer Center and Georgia Regents University finds that a protein that fuels an inflammatory pathway does not turn off in breast cancer, resulting in an increase in cancer stem cells. This provides a potential target for treating triple negative breast cancer, the most aggressive form of the disease.

17 Feb 2014

Receptor News and Research

Lung cancer patients with Del19 mutation benefit most from afatinib

Certain fragments of DNA shed by tumors can be used to non-invasively screen for early-stage cancers

Deficiency in SNX27 explains learning impairment in Down's syndrome

PBL Assay Science, HumanZyme ink licensing agreement to expand reagent offerings

Eleven Biotherapeutics announces first pivotal Phase 3 clinical study of EBI-005 for treatment of DED

Taste receptors act as first line sentinels against infection in upper airway

Researchers discover protein for treatment of anaplastic thyroid carcinoma

NPS Pharmaceuticals reports net global product sales of $15.3 million for Q4 2013

IGF1R linked to mutation-negative lung cancer erlotinib resistance

Study shows how immune system reconstitutes itself following immune-depleting therapy

NUS researchers discover promising treatment for anaplastic thyroid carcinoma

Researchers detail how psoralen blocks signaling pathway of HER2-positive cancers

Afatinib ‘first line’ for advanced mutation-positive lung cancer

Study points to unique therapeutic approach for managing muscle-wasting conditions

New research points to potential target for treating triple negative breast cancer

Research findings have important implications for personalized treatment of alcohol abuse

Study shows how Bcl-2 cancer-related protein signals cancer cells to live longer

Researchers personalize drug treatments for cholangiocarcinoma using genomic sequencing

Topiramate reduces drinking in patients committed to abstinence from alcohol

Common mutations produce typical schizophrenia brain changes

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News